Healthcare · Profile from Healthcare Research Companion
Rite Aid Corporation
The Pennsylvania discount drugstore chain that grew by acquisition into America's third-largest pharmacy operator, and then spent a quarter of a century paying for it. Its story includes one of the largest accounting frauds of the 1990s, a debt-funded purchase of Eckerd and Brooks at the top of the market, a pharmacy benefit manager bought too late, two failed sales (to Walgreens and to Albertsons), opioid litigation, and two Chapter 11 filings in under two years. The second ended with every store closed in 2025. Rite Aid is the clearest case in US healthcare of a retail pharmacy without scale leadership, a PBM or an insurer being squeezed until it broke.
At a glance
- Founded
- September 1962, Scranton, Pennsylvania, as Thrift D Discount Center; renamed Rite Aid in 1968
- Founders
- Alex Grass, with backing from the Lehrman family's wholesale grocery business (reported)
- Headquarters
- Camp Hill, Pennsylvania, for most of its history; headquarters moved to a smaller "remote-first" office at the Philadelphia Navy Yard (announced September 2021, opened 2022)
- Ownership / structure
- Public from 1968 (NYSE for most of its life; NYSE: RAD); delisted and controlled by lenders after the first Chapter 11 (emerged 2024); liquidated in the second Chapter 11 (2025)
- Leadership (history)
- Alex Grass (founder, CEO to 1995); Martin Grass (CEO 1995–1999); Robert Miller (CEO 1999–2003); Mary Sammons (CEO 2003–2010); John Standley (CEO 2010–2019); Heyward Donigan (CEO 2019–2022); Elizabeth Burr (interim, 2022–23); Jeffrey Stein (CEO and chief restructuring officer, October 2023–September 2024); Matt Schroeder (former CFO, CEO from emergence in September 2024 to the 2025 wind-down)
- Segment
- Retail pharmacy (Retail Pharmacy segment) and, from 2015 to 2024, pharmacy services (EnvisionRx, later Elixir: PBM, mail and specialty pharmacy, Medicare Part D plan)
- Payer and patient
- Prescription revenue paid mostly by PBMs on behalf of commercial plans, Medicare Part D and Medicaid; front-store sales paid by consumers
- Scale
- Peak of ~5,000+ stores in 31 states after the 2007 Eckerd/Brooks deal (reported ~5,059); ~4,500 stores before the 2018 sale to Walgreens; 2,550 in March 2018 after it (10-K); ~2,100 at the October 2023 filing; ~1,245 at the May 2025 filing; zero by 3 October 2025
- Revenue
- ~$26bn (fiscal 2008); peak ~$32bn+ (around fiscal 2017, including EnvisionRx); ~$24bn (fiscal 2023) (approximate, from filings)
- Signature moves (incl. failures)
- Founding and discount roll-up (1962); accounting fraud and founder-family ouster (1999); Eckerd/Brooks acquisition (2007); EnvisionRx PBM (2015); Walgreens merger blocked and store sale (2015–18); Albertsons merger collapse (2018); first Chapter 11 (2023); second Chapter 11 and liquidation (2025)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1962
Founding Thrift D Discount
Founding / launch, followed by an acquisition-led roll-up
1999
Accounting Fraud and Grass Ouster
Restructuring / leadership change / regulatory settlement
2007
Eckerd and Brooks Acquisition
Acquisition
2015
EnvisionRx PBM Acquisition
Acquisition (vertical integration into pharmacy benefit management)
2015
Walgreens Merger Blocked
Merger (failed) / divestiture
2018
Albertsons Merger Collapse
Merger (failed)
2023
First Chapter 11
Bankruptcy / restructuring
2025
Second Bankruptcy and Liquidation
Bankruptcy / shutdown